TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Apple Turns 50: From Garage Startup to AI Crossroads 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
MALVERN, Pa., Jan. 03, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led clinical-stage pharmaceutical company focused on defining new standards of care in medical and aesthetic dermatology, today announced that it plans to present at the 35th Annual J.P. Morgan Healthcare Conference. Aclaris President and Chief Executive Officer Dr. Neal Walker will present on Wednesday, January 11, 2016 at 3:30 pm PT (6:30 pm ET) at The Westin St. Francis in San Francisco.
A live audio webcast of the presentation will be available on the Investors section of the company's website, www.aclaristx.com. A replay will be available after the event.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
